Icon surges 14% as Q2 earnings beat estimates, guidance raised

Published 23/07/2025, 21:56
Icon surges 14% as Q2 earnings beat estimates, guidance raised

Investing.com -- Icon plc (NASDAQ:ICLR), a global clinical research organization, saw its shares surge 14.6% in afterhours trading after reporting second-quarter earnings that exceeded analyst expectations and raising its full-year guidance.

The Dublin-based company reported adjusted earnings of $3.26 per diluted share for the second quarter, beating analyst estimates of $3.19. Revenue came in at $2.02 billion, surpassing the consensus estimate of $1.98 billion, though this represents a 4.8% decrease compared to the same quarter last year.

Icon raised its full-year 2025 revenue guidance to a range of $7.85-$8.15 billion, an increase of $50 million at the midpoint from its previous forecast. The company also updated its adjusted earnings per share guidance to a range of $13.00-$14.00.

"ICON made solid progress in quarter two despite the continuing challenges within the clinical development and macro-economic environments," said CEO Dr. Steve Cutler. "ICON’s innovative solutions continue to resonate with customers, leading to strong progression in gross business wins in the quarter, which increased 11% sequentially over quarter one."

The company reported gross business wins of $2.97 billion in the quarter, representing a 10.6% increase from the first quarter. Net business wins were $2.06 billion, resulting in a book-to-bill ratio of 1.02.

Adjusted EBITDA for the quarter was $396 million, or 19.6% of revenue, a 1.4% increase from the first quarter but a 12.1% decrease from the second quarter of 2024.

Icon’s board authorized an expansion of $500 million to its current share repurchase program, bringing the total value of authorized share repurchases to $1 billion. During the quarter, the company repurchased $250 million worth of stock at an average price of $146 per share.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.